Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab

CONCLUSIONS: Malignant diseases, additional chemotherapy, DNO dosage, and oral inflammations as well as diabetes mellitus and hypertension influence MRONJ onset in patients treated with DNO significantly.CLINICAL RELEVANCE: Patients receiving ART with DNO featuring aforementioned risk factors have a higher risk of MRONJ onset. These patients need a sound and regular prophylaxis in order to prevent the onset of MRONJ under DNO treatment.PMID:34812959 | DOI:10.1007/s00784-021-04261-4

Source: Clinical Genitourinary Cancer - November 23, 2021 Category: Cancer & Oncology Authors: Alexander Wick Philipp Bankosegger Sven Otto Bettina Hohlweg-Majert Timm Steiner Florian Probst Oliver Ristow Christoph Pautke Source Type: research